Kirby McInerney LLP Reminds West Pharmaceutical Services, Inc. (WST) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors who purchased West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE:WST) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at [e-mail], or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud class action lawsuit against the Company.

[CONTACT FORM]

The lawsuit was filed on behalf of investors who acquired West securities during the period from February 16, 2023, through February 12, 2025 (“the Class Period”). Investors have until July 7, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.

On February 13, 2025, when West issued extremely weak 2025 revenue and earnings forecasts, West attributed the disappointing guidance in part on CM headwinds, including the loss of two major continuous glucose monitoring (“CGM”) customers that had begun transitioning to in-house manufacturing of next generation devices after West “made the decision to not participate going forward as our financial thresholds cannot be achieved.” West also revealed that its SmartDose wearable injector devices would be “margin dilutive” in 2025 and that it would be “taking steps to improve [its SmartDose] economics, and all options are on the table.” On this news, the price of West shares declined by $123.17 per share, or approximately 38%, from $322.28 per share on February 12, 2025, to close at $199.11 on February 13, 2025.

The complaint alleges that defendants, throughout the Class Period, failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin HVP portfolio; (2) West’s SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company’s profit margins due to operational inefficiencies; and (3) these margin pressures created the risk of costly restructuring activities, including the Company’s exit from CGM contracts with long-standing customers.

[LEARN MORE ABOUT THE CLASS ACTION]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.